The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 10, 2024

Filed:

Oct. 06, 2017
Applicants:

Virginia Tech Intellectual Properties, Inc., Blacksburg, VA (US);

Wake Forest University Health Sciences, Winston-Salem, NC (US);

Inventors:

Jill W. Ivey, Blacksburg, VA (US);

Eduardo L. Latouche, Blacksburg, VA (US);

Scott S. Verbridge, Blacksburg, VA (US);

Rafael V. Davalos, Blacksburg, VA (US);

Glenn J. Lesser, Winston-Salem, NC (US);

Waldemar Debinski, Blacksburg, VA (US);

Assignees:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61N 1/32 (2006.01); A61B 18/12 (2006.01); A61K 38/19 (2006.01); A61N 1/05 (2006.01); A61N 1/06 (2006.01); A61B 17/00 (2006.01); A61B 18/00 (2006.01); A61K 38/17 (2006.01);
U.S. Cl.
CPC ...
A61N 1/327 (2013.01); A61B 18/12 (2013.01); A61B 18/1233 (2013.01); A61K 38/19 (2013.01); A61N 1/05 (2013.01); A61N 1/06 (2013.01); A61B 2017/00172 (2013.01); A61B 2018/00613 (2013.01); A61B 2018/00732 (2013.01); A61B 2018/00767 (2013.01); A61B 2018/126 (2013.01); A61B 2018/128 (2013.01); A61K 38/1793 (2013.01);
Abstract

Described herein are methods of electroporation that can include the steps of contacting a cell that is responsive to an EphA2 receptor ligand with an amount of an EphA2 receptor ligand and applying high-frequency irreversible electroporation to the cell. Also described herein are methods of treating cancer in a subject in need thereof, wherein the methods can include the steps of administering an amount of an EphA2 receptor ligand and applying high-frequency irreversible electroporation to a location on or within the subject.


Find Patent Forward Citations

Loading…